

**FOOD AND DRUG ADMINISTRATION (FDA)  
Center for Biologics Evaluation and Research (CBER)  
165<sup>th</sup> Meeting of the Vaccines and Related Biological Products Advisory  
Committee  
Silver Spring, MD  
March 5, 2021  
AGENDA**

**Topic:** The Committee will meet in open session to discuss and make recommendations on the selection of strains to be included in the influenza virus vaccines for the 2021 – 2022 influenza season.

<b>Time</b>	<b>Presentation/Presenter</b>
<b>9:00am – 9:10am</b>	<b><u>Opening Remarks: Call to Order, Introduction of Committee</u></b> Hana El Sahly, M.D., Chair, VRBPAC
<b>9:10am – 9:30am</b>	<b><u>Administrative Announcements, Roll Call, Introduction of Committee, Conflict of Interest Statement</u></b> Kathleen Hayes, M.P.H. Designated Federal Officer, VRBPAC CBER, FDA
<b>9:30am – 9:45am</b>	<b><u>Introduction</u></b> Jerry Weir, Ph.D. Director Division of Viral Products (DVP) Office of Vaccines Research and Review (OVRR) CBER, FDA  Q &A: 5 min
<b>9:45am – 10:10am</b>	<b><u>U.S. Surveillance</u></b> Lisa Grohskopf, M.D., M.P.H. CAPT USPHS Associate Chief for Policy & Liaison Activities, Epidemiology & Prevention Branch, Influenza Division Centers for Disease Control and Prevention (CDC)  Q &A: 5 min
<b>10:10am – 11:20am</b>	<b><u>Global Influenza Virus Surveillance and Characterization</u></b> David Wentworth, Ph.D. Branch Chief Influenza Division Virology, Surveillance, and Diagnostic Branch Centers for Disease Control and Prevention (CDC)  Q &A: 10 min

**FOOD AND DRUG ADMINISTRATION (FDA)**  
**Center for Biologics Evaluation and Research (CBER)**  
**165<sup>th</sup> Meeting of the Vaccines and Related Biological Products Advisory**  
**Committee**  
**Silver Spring, MD**  
**March 5, 2021**  
**AGENDA**

<b>11:20am – 11:30am</b>	<b>BREAK</b>
<b>11:30am – 11:55am</b>	<p><b><u>DoD Vaccine Effectiveness Report</u></b>  LTC Kevin Taylor, M.D., MTM&amp;H  Focus Area Chief  Global Emerging Infections Surveillance Branch  Armed Forces Health Surveillance Division  Public Health Division - DHA</p> <p>Kathleen Creppage, DrPh., M.P.H  Senior Epidemiologist  Armed Forces Health Surveillance Division  Global Emerging Infections Surveillance Branch</p> <p>Q &amp;A: 5 min</p>
<b>11:55am – 12:20pm</b>	<p><b><u>Candidate Vaccine Strains &amp; Potency Reagents</u></b>  Manju Joshi, Ph.D.  Lead Biologist  Division of Biological Standards &amp; Quality  Office of Compliance and Biologics Quality  CBER/FDA</p> <p>Q &amp;A: 5 min</p>
<b>12:20pm – 12:45pm</b>	<p><b><u>Comments from Manufacturer Representative</u></b>  Lauren Parker, Ph.D.  AstraZeneca</p> <p>Q &amp;A: 5 min</p>
<b>12:45pm – 1:30pm</b>	<b>Lunch (45 min.)</b>
<b>1:30pm – 2:30pm</b>	<b>Open Public Hearing (60 min.)</b>
<b>2:30pm – 3:30pm</b>	<b><u>Committee Discussion, Recommendations, and Vote</u></b>
<b>3:30 pm</b>	<b>Adjourn Meeting</b>